RT Journal Article
SR Electronic
T1 Lung transplantation for pulmonary fibrosis secondary to severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.26.20218636
DO 10.1101/2020.10.26.20218636
A1 Ankit Bharat
A1 Melissa Querrey
A1 Nikolay S. Markov
A1 Samuel Kim
A1 Chitaru Kurihara
A1 Rafael Garza-Castillon
A1 Adwaiy Manerikar
A1 Ali Shilatifard
A1 Rade Tomic
A1 Yuliya Politanska
A1 Hiam Abdala-Valencia
A1 Anjana V. Yeldandi
A1 Jon W. Lomasney
A1 Alexander V. Misharin
A1 G.R. Scott Budinger
YR 2020
UL http://medrxiv.org/content/early/2020/10/27/2020.10.26.20218636.abstract
AB Lung transplantation can potentially be a life-saving treatment for patients with non-resolving COVID-19 acute respiratory distress syndrome. Concerns limiting transplant include recurrence of SARS-CoV-2 infection in the allograft, technical challenges imposed by viral-mediated injury to the native lung, and potential risk for allograft infection by pathogens associated with ventilator-induced pneumonia in the native lung. Additionally, the native lung might recover, resulting in long-term outcomes preferable to transplant. Here, we report the results of the first two successful lung transplantation procedures in patients with non-resolving COVID-19 associated acute respiratory distress syndrome in the United States. We performed smFISH to detect both positive and negative strands of SARS-CoV-2 RNA in the explanted lung tissue, extracellular matrix imaging using SHIELD tissue clearance, and single cell RNA-Seq on explant and warm post-mortem lung biopsies from patients who died from severe COVID-19 pneumonia. Lungs from patients with prolonged COVID-19 were free of virus but pathology showed extensive evidence of injury and fibrosis which resembled end-stage pulmonary fibrosis. Single cell RNA-Seq of the explanted native lungs from transplant and paired warm post-mortem autopsies showed similarities between late SARS-CoV-2 acute respiratory distress syndrome and irreversible end-stage pulmonary fibrosis requiring lung transplantation. There was no recurrence of SARS-CoV-2 or pathogens associated with pre-transplant ventilator associated pneumonias following transplantation in either patient. Our findings suggest that some patients with severe COVID-19 develop fibrotic lung disease for which lung transplantation is the only option for survival.Single sentence summary Some patients with severe COVID-19 develop end-stage pulmonary fibrosis for which lung transplantation may be the only treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institutes of Health, NIH HL145478, HL147290, and HL147575 to AB; NIH U19AI135964, P01AG049665, R01HL153312, NUCATS COVID-19 Rapid Response Grant, CZI Seed Networks for the Human Cell Atlas to AVM, and P01AG049665, R01HL147575, U19AI135964, and Veterans Affairs grant I01CX001777 to GRSB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Northwestern University STU00212120, STU00213177, STU00212511 and STU00212579.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCounts tables and integrated objects are available through GEO with accession number GSE158127. Raw data is in the process of being deposited to SRA/dbGaP.